Please login to the form below

Not currently logged in

Celgene to acquire biotech firm Quanticel Pharmaceuticals

Firm hopes to expand its pipeline of life-enhancing products for cancer patients

Celgene building 

Celgene has acquired privately owned biotech Quanticel Pharmaceuticals, which has a focus on cancer drug discovery.

Through the agreement, Celgene will have full access to Quanticel's proprietary platform for the single-cell genomic analysis of human cancer, alongside Quanticel's lead programmes that target specific epigenetic modifiers. 

It is hoped they will advance Celgene's pipeline of innovative cancer therapies.

The new acquisition marks the end of a 2011 strategic alliance between the two companies, during which Quanticel industrialised its single-cell platform for analysis of tumour cellular content and applied it to novel target discovery.

Steve Kaldor, CEO at Quanticel, commented: “Celgene made clear from the start that they valued both our technology and out team and this resulted in an extremely collaborative and productive partnership over the past three years.

“We look forward to supporting the continued maturation of our pipeline and platform as a part of the Celgene organisation.”

Celgene will acquire Quanticel for an upfront payment of $100m in cash, while up to an additional $385m in contingent payments may be achieved with research, development and regulatory advances related to Quanticels's R&D platform.

Multiple drug candidates from Quanticel are expected to enter clinical trials in early 2016.

This month, it was revealed that Celgene spent $45m on a minority stake into Australian stem cell drug manufacturer Mesoblast.




Article by
Kirstie Pickering

28th April 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...